ROR1 and diffuse large B-cell lymphoma: In this study, we explored clinical and functional inhibitory aspects of ROR1 in DLBCL and showed—in preliminary analyses, and with a limited number of patients—that ROR1 expression was more often observed in primary refractory DLBCL than in relapsed and non-relapsed patients, that overall survival may be related to ROR1 expression, and that a second-generation small molecule ROR1 inhibitor induced the apoptosis of ROR1+ DLBCL cell lines in vitro and in a zebra fish model.